Currently, the traditional disease activity of Takayasu arteritis is mainly based on National Institutes of Health criteria and the inactive cases don't need anti-inflammatory treatment. However, pathologic findings showed that there was still inflammatory activity in the affected vessels, and the follow-up data also found significant lesion progression in some inactive cases. Sixty inactive Takayasu arteritis patients will be recruited to determine whether these individuals are active by screening new inflammatory markers in this study. New inflammatory markers included tumor necrosis factor,interleukin-2,interleukin-6,interleukin-8,interleukin-10,high-sensitivity C-reactive protein, and 18f-FDG positron emission tomograph. According to new inflammatory markers, sixty patients will be divided into two categories: inactive patients (n=20) and active patients (n=40). And then, Forty active patients diagnosed by new inflammatory markers will be randomly assigned to either anti-inflammatory therapy group or control group. The changes of inflammatory activity and lesion progression will be observed during one-year follow up in all 60 patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Prednisone 0.5mg/(kg•d) and/or cyclophosphamide 2mg/kg
Lesion progression
Progression of previous lesion degree\>20% or new lesion
Time frame: baseline and 12 months
Lesion progression
Progression of previous lesion degree\>20% or new lesion
Time frame: baseline, 3 months, 6 months, 9 months
Changes in plasma concentration of tumor necrosis factor
Time frame: baseline, 3 months, 6 months, 9 months and 12 months
Changes in plasma concentration of interleukin-2
Time frame: baseline, 3 months, 6 months, 9 months and 12 months
Changes in plasma concentration of interleukin-6
Time frame: baseline, 3 months, 6 months, 9 months and 12 months
Changes in plasma concentration of interleukin-8
Time frame: baseline, 3 months, 6 months, 9 months and 12 months
Changes in plasma concentration of interleukin-10
Time frame: baseline, 3 months, 6 months, 9 months and 12 months
Changes in plasma concentration of high-sensitivity C-reactive protein
Time frame: baseline, 3 months, 6 months, 9 months and 12 months
Changes in 18F-fluorodeoxyglucose uptake by positron emission tomograph
Time frame: baseline, 3 months, 6 months, 9 months and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.